Publications by authors named "Janette Mansour"
Article Synopsis
- COVID-19 poses significant risks for patients with end-stage renal disease (ESRD), with a study showing 5.5% of 2336 dialysis patients diagnosed with the virus.
- Among those followed for over 28 days, 37% experienced severe outcomes and 28% died, with oxygen therapy and decreased lymphocyte counts identified as major risk factors.
- The study noted that chronic use of angiotensin II receptor blockers (ARBs) may protect against mortality, while treatments like azithromycin and hydroxychloroquine showed no benefit for patients with COVID-19.
Background: Nicotinamide (NAM) has been proposed as an alternative treatment to phosphate binders for hyperphosphataemia in chronic kidney disease.
Methods: The NICOREN multicentre, open-label and randomized study was designed to examine non-inferiority and safety of NAM when compared with sevelamer (SEV) in chronic haemodialysis patients. One hundred patients were randomized to either NAM or SEV treatment for 24 weeks.
Article Synopsis
- Diuretics are agents that help the body remove excess sodium and water by affecting how sodium is reabsorbed in the kidneys, and different types of diuretics work in various ways, leading to different side effects and effects on sodium levels.
- The effectiveness of a diuretic can be influenced by factors like kidney function and existing health issues such as nephrotic syndrome, with potential solutions including dose adjustments and specific drug interactions.
- They are primarily used to treat conditions like systemic edema and hypertension, often in combination with thiazide and potassium-sparing diuretics for optimal results in blood pressure management.
Most of the deleterious effects of angiotensin II (Ang II) on blood pressure (BP), cardiovascular remodeling, and atherosclerosis are mediated by Ang II type 1 (AT1)-receptor activation. This explains why Ang-II-decreasing or blocking drugs have been successful in decreasing global cardiovascular morbimortality in patients with cardiac complications. However, in primary or secondary stroke prevention trials in patients with low cardiac risk, b-blockers and angiotensin-converting enzyme inhibitors (ACEIs), which decrease Ang II formation, seem to be less protective than thiazides and dihydropyridines, which increase Ang II.
View Article and Find Full Text PDF